Literature DB >> 8866714

Conditioned place preference and locomotor activation produced by injection of psychostimulants into ventral pallidum.

W Gong1, D Neill, J B Justice.   

Abstract

The ventral pallidum (VP) is often viewed as an output structure of the nucleus accumbens septi (NAS). However, VP, like NAS, receives a dopaminergic input from the ventral tegmental area. These experiments investigated some behavioral effects of microinjection into VP of drugs which enhance dopaminergic transmission. Injection of 25 micrograms dopamine or 5-10 micrograms amphetamine into VP produced hypermotility. In contrast, injection of 12.5-50 micrograms cocaine initially suppressed, then increased, activity. Injection of 100 micrograms cocaine only produced hypomotility in the 1-h period examined. The hypomotility following cocaine seemed to be a local anesthetic effect, because it was mimicked by 50-200 micrograms procaine. Procaine did not, however, produce subsequent hypermotility. Conditioned place preference (CPP) was produced by 10 micrograms amphetamine and 50 micrograms cocaine but not 100 micrograms procaine. We conclude that injection of cocaine into VP unlike similar injections into NAS, produces CPP. These results support the idea of an involvement of dopamine in VP in reward and locomotor activation, independent of dopamine in NAS. The use of intracerebral injections of cocaine is complicated, however, by an apparent local anesthetic effect of the drug.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866714     DOI: 10.1016/0006-8993(95)01222-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  33 in total

Review 1.  The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors.

Authors:  David H Root; Roberto I Melendez; Laszlo Zaborszky; T Celeste Napier
Journal:  Prog Neurobiol       Date:  2015-04-06       Impact factor: 11.685

2.  Relative contributions and mapping of ventral tegmental area dopamine and GABA neurons by projection target in the rat.

Authors:  Jocelyn M Breton; Annabelle R Charbit; Benjamin J Snyder; Peter T K Fong; Elayne V Dias; Patricia Himmels; Hagar Lock; Elyssa B Margolis
Journal:  J Comp Neurol       Date:  2018-12-11       Impact factor: 3.215

Review 3.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

4.  Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine.

Authors:  Paul Marquez; Ramkumarie Baliram; Nagaraju Gajawada; Theodore C Friedman; Kabirullah Lutfy
Journal:  Behav Neurosci       Date:  2006-02       Impact factor: 1.912

Review 5.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

6.  Presynaptic versus postsynaptic localization of mu and delta opioid receptors in dorsal and ventral striatopallidal pathways.

Authors:  M F Olive; B Anton; P Micevych; C J Evans; N T Maidment
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

Review 7.  Ventral pallidum roles in reward and motivation.

Authors:  Kyle S Smith; Amy J Tindell; J Wayne Aldridge; Kent C Berridge
Journal:  Behav Brain Res       Date:  2008-10-08       Impact factor: 3.332

Review 8.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

9.  Serotonin(2C) receptors in the ventral pallidum regulate motor function in rats.

Authors:  Steven M Graves; Annika A Viskniskki; Kathryn A Cunningham; T Celeste Napier
Journal:  Neuroreport       Date:  2013-08-07       Impact factor: 1.837

10.  A neural computational model of incentive salience.

Authors:  Jun Zhang; Kent C Berridge; Amy J Tindell; Kyle S Smith; J Wayne Aldridge
Journal:  PLoS Comput Biol       Date:  2009-07-17       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.